Vina Leite
About Vina Leite
Vina Leite (age 56) is an independent Class II director of DocGo Inc. (DCGO), serving since 2022, and is Chief People Officer of GoodRx, Inc. (Nasdaq: GDRX) since 2022. She previously held senior human capital roles at The Trade Desk (2019–2022), Cylance (2016–2019), and QLogic (2014–2016). She holds a bachelor’s degree in Management from Rhode Island College and a Master’s in Organizational Management from Capella University .
Past Roles
| Organization | Role | Tenure | Notes/Impact |
|---|---|---|---|
| GoodRx, Inc. | Chief People Officer | 2022–present | Public company CPO overseeing human capital at scale |
| The Trade Desk | Chief People Officer | 2019–2022 | Human capital leadership at a large-cap adtech firm |
| Cylance Inc. | Chief People Officer | 2016–2019 | Led people operations through rapid growth; recognized as a top workplace; departed upon BlackBerry acquisition |
| QLogic | SVP & Chief Human Resource Officer | 2014–2016 | Senior HR leadership for a tech hardware firm |
External Roles
| Organization | Role | Type | Committees/Impact |
|---|---|---|---|
| Jamf Holding Corp. (Nasdaq: JAMF) | Director | Public company | Current directorship |
| AHEAD | Director | Private company | Current directorship |
| Collectors Universe, Inc. | Director (prior) | Public (taken private in 2021) | Served until take-private in 2021 |
Board Governance
- Board class and term: Class II; term expires at the 2026 Annual Meeting .
- Independence: Determined independent under Nasdaq rules; satisfies heightened Compensation Committee independence standards .
- Committee assignments: Compensation Committee (Member); Nominating & Corporate Governance Committee (Member) .
- Committee chairs: Not a chair; Compensation Committee Chair is Ira Smedra; NCGC Chair is Ira Smedra .
- 2024 meeting activity: Board held 11 meetings; every director attended at least 75% of Board and assigned committee meetings .
- Committee meetings in 2024: Compensation Committee 7; Nominating & Corporate Governance Committee 3 .
- Executive sessions: Independent directors meet in executive session at every regular Board meeting; chaired by the independent Board Chair .
Fixed Compensation
- 2024 Director compensation (DocGo-specific):
- Annual compensation received by Leite in 2024: $150,000 in RSUs; no cash fees; no option awards; total $150,000 .
- As of 12/31/2024, each non-executive director (other than the Chair) held 34,965 RSUs from the December 13, 2024 grant (priced at $4.29) .
- 2025 standard non-executive director program (policy framework):
- Annual cash retainer: $55,000; Committee retainers: Compensation (Member $10,000; Chair $20,000), Nominating & Corporate Governance (Member $5,000; Chair $10,000) .
- Annual equity: $150,000 in RSUs, one-year cliff vest; initial option grant up to $300,000 (3-year ratable vest) at committee discretion .
- Director stock ownership guidelines adopted Feb 2025: 5× annual cash retainer within five years; all non-executive directors were in compliance or on track at adoption .
| Director Compensation (2024) | Cash Fees ($) | Stock Awards ($) | Option Awards ($) | Total ($) |
|---|---|---|---|---|
| Vina Leite | $0 | $150,000 | $0 | $150,000 |
| 2025 Director Compensation Framework | Amount |
|---|---|
| Annual Cash Retainer | $55,000 |
| Annual Equity (RSUs) | $150,000; 1-year cliff |
| Compensation Committee (Member/Chair) | $10,000 / $20,000 |
| Nominating & Corporate Governance (Member/Chair) | $5,000 / $10,000 |
| Initial Options (first year) | Up to $300,000; 3-yr vest |
Performance Compensation
- Director pay at DocGo is not tied to financial/ESG performance metrics; equity is time-based (RSUs) and option awards (where applicable) have service-based vesting schedules under the standard program .
| Performance-linked Director Pay Elements | Detail |
|---|---|
| Metrics in director compensation | None disclosed; RSUs time-based; standard initial options time-based |
Other Directorships & Interlocks
- Current public company directorships: Jamf Holding Corp. (JAMF) .
- Private/non-public roles: AHEAD board .
- Prior public company board: Collectors Universe (until 2021 take-private) .
- Compensation Committee interlocks: None—committee members (including Leite) had no relationships requiring Item 404 disclosure in 2024; no executive officer cross-membership interlocks reported .
Expertise & Qualifications
- Human capital leadership at public technology and healthcare companies; recognized experience scaling organizations through growth and M&A (Cylance acquisition by BlackBerry) .
- Professional affiliations: National Human Resources Association; Society for Human Resource Management .
- Education: B.S. in Management (Rhode Island College); M.S. in Organizational Management (Capella University) .
Equity Ownership
- Beneficial ownership (as of April 4, 2025): 70,728 shares; <1% of outstanding .
- RSUs held (as of 12/31/2024): 34,965 RSUs (standard director grant on Dec 13, 2024) .
- Stock options outstanding (as of 12/31/2024): 81,425 options (director-level options outstanding count) .
- Stock ownership guidelines (directors): 5× annual cash retainer within five years; status: all non-exec directors in compliance or on track as of adoption (Feb 2025) .
- Hedging/derivatives prohibitions: Company policy prohibits short-term trading, short sales, and transactions in publicly-traded options and all hedging transactions by directors .
| Ownership & Alignment | Detail |
|---|---|
| Beneficially owned shares | 70,728; <1% of outstanding (as of 4/4/2025) |
| RSUs outstanding | 34,965 RSUs (12/13/2024 grant; 1-yr cliff) |
| Options outstanding | 81,425 options (director-level outstanding as of 12/31/2024) |
| Ownership guideline | 5× cash retainer within 5 years; in compliance/on track |
| Hedging policy | Hedging and short sales prohibited for directors |
Governance Assessment
-
Strengths:
- Independent director with HR/people operations expertise; serves on Compensation and Nominating & Corporate Governance Committees; meets heightened independence standards for Compensation Committee .
- Attendance: Board reported all directors met at least the 75% attendance threshold in 2024; Board held 11 meetings; CC met 7; NCGC met 3 .
- Director compensation structure aligned with market: balanced cash/equity framework; stock ownership guidelines adopted (5× cash retainer) to reinforce alignment .
- Anti-hedging policy for directors supports alignment and risk mitigation .
- Compensation Committee uses independent consultant (Compensia); committee independence reviewed with no conflicts disclosed .
-
Watch items / investor confidence signals:
- 2024 say‑on‑pay support was 72.4%, indicating moderate dissent and ongoing investor scrutiny of pay design; the committee subsequently incorporated relative TSR PSUs for 2025 LTI to strengthen pay-for-performance .
- Board pursuing amendments to corporate opportunity and officer exculpation provisions following stockholder litigation challenging the breadth of prior corporate opportunity renunciation; while company denies wrongdoing, revisions and votes are being sought in 2025, which investors may monitor for governance posture and protections .